Original Article Open Access
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Mar 21, 2013; 19(11): 1749-1759
Published online Mar 21, 2013. doi: 10.3748/wjg.v19.i11.1749
Effects of hypoxia-inducible factor-1α silencing on the proliferation of CBRH-7919 hepatoma cells
Lin-Feng Xu, Jia-Yan Ni, Hong-Liang Sun, Yao-Ting Chen, Department of Interventional Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510210, Guangdong Province, China
Yu-Dan Wu, Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510210, Guangdong Province, China
Author contributions: Xu LF and Ni JY contributed equally to this work; Ni JY performed the majority of experiments; Sun HL and Chen YT provided vital reagents and analytical tools and were also involved in editing the manuscript; Xu LF and Wu YD provided the financial support for this work and designed the study; Ni JY wrote the manuscript.
Supported by Natural Science Foundation of Guangdong Province People’s Republic of China, No. 10151008901000182
Correspondence to: Yu-Dan Wu, MD, Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510210, Guangdong Province, China. wu_yudan@126.com
Telephone: +86-20-81332442 Fax: +86-20-81332442
Received: November 22, 2012
Revised: January 8, 2013
Accepted: January 17, 2013
Published online: March 21, 2013
Processing time: 120 Days and 2.2 Hours

Abstract

AIM: To study the effects of hypoxia-inducible factor-1α (HIF-1α) silencing on the proliferation of hypoxic CBRH-7919 rat hepatoma cells.

METHODS: The CBRH-7919 rat hepatoma cell line was used in this study and the hypoxic model was constructed using CoCl2. The HIF-1α-specific RNAi sequences were designed according to the gene coding sequence of rat HIF-1α obtained from GeneBank. The secondary structure of the HIF-1α gene sequence was analyzed using RNA draw software. The small interfering RNA (siRNA) transfection mixture was produced by mixing the siRNA and Lipofectamine2000TM, and transfected into the hypoxic hepatoma cells. Real time reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting assay were used to detect the expression levels of mRNA and protein. HIF-1α and vascular endothelial growth factor (VEGF) mRNA was determined using real time RT-PCR; the protein expression levels of AKT, p-AKT, p21 and cyclinD1 were determined using Western blotting. The proliferation of hepatoma cells was observed using the methyl thiazolyl tetrazolium (MTT) assay and the bromodeoxyuridine (BrdU) incorporation cell proliferation assay.

RESULTS: Under induced hypoxia, the viability of the hepatoma cells reached a minimum at 800 μmol/L CoCl2; the viability of the cells was relatively high at CoCl2 concentrations between 100 μmol/L and 200 μmol/L. Under hypoxia, the mRNA and protein expression levels of HIF-1α and VEGF were significantly higher than that of hepatoma cells that were cultured in normaxia. HIF-1α-specific RNAi sequences were successfully transfected into hepatoma cells. The transfection of specific siRNAs significantly inhibited the mRNA and protein expression levels of HIF-1α and VEGF, along with the protein expression levels of p-AKT and cyclinD1; the protein expression of p21 was significantly increased, and there was no significant difference in the expression of AKT. The MTT assay showed that the amount of hepatoma cells in S phase in the siRNA transfection group was obviously smaller than that in the control group; in the siRNA transfection group, the amount of hepatoma cells in G1 phase was more than that in the control group. The BrdU incorporation assay showed that the number of BrdU positive hepatoma cells in the siRNA transfection group was less than that in the control group. The data of the MTT assay and BrdU incorporation assay suggested that HIF-1α silencing using siRNAs significantly inhibited the proliferation of hepatoma cells.

CONCLUSION: Hypoxia increases the expression of HIF-1α, and HIF-1α silencing significantly inhibits the proliferation of hypoxic CBRH-7919 rat hepatoma cells.

Key Words: RNA interference; Hypoxia-inducible factor-1α; Vascular endothelial growth factor; Protein kinase B; CBRH-7919 hepatoma cells

INTRODUCTION

Hepatocellular carcinoma (HCC) is one of the most common malignancies. HCC accounts for more than 660 000 new cases of cancer arising annually all around the world[1,2]. HCC is a highly malignant tumor and the majority of HCC patients are diagnosed at the intermediate or advanced stages of tumor growth. HCC is often accompanied by poor liver function, which makes surgical resection impossible. Liver transplantation is one treatment option for HCC patients. However, the availability of organ donors limits the application of this treatment. Currently, nonsurgical therapy has been accepted as the main treatment for HCC, and gene therapy for the treatment of HCC has begun to attract increasing attention. RNA interference is a powerful method for the knockdown of pathologically relevant genes. Small interfering RNAs (siRNAs) have been widely demonstrated as effective biomedical genetic-therapy applications for many diseases[3,4]. siRNAs induce sequence-specific gene silencing of the target mRNAs to which they are perfectly complementary by directing the RNA-induced silencing complex to mediate site-specific cleavage, thus destroying the targeted mRNA[5]. In view of its powerful gene-silencing properties, RNAi has been proposed as an important option to validate new therapeutic targets and to develop innovative anticancer therapies.

Intratumoral hypoxia is a common finding in human cancers and associated with an increased risk of tumor regeneration, invasion, metastasis and patient mortality[6]. Hypoxia inducible factor-1 (HIF-1) functions as a master regulator of oxygen homeostasis in almost all nucleated mammalian cells and is composed of the constitutively expressed HIF-1β subunit and the highly regulated HIF-1α subunit. The HIF-1α subunit is the functional subunit of HIF-1 and plays a critical role in cellular adaptation to change in oxygen availability[7-9]. HIF-1α is a central transcription factor produced by tumor cells under hypoxic conditions and is a key regulator of several genes that are important in cancer biology. Over-expression of HIF-1α in human tumors is associated with poor prognosis and poor therapeutic outcomes, and HIF-1α has been suggested as a significant target for cancer therapy[10,11].

According to previous studies[12-14], it is possible to silence HIF-1α using siRNA interference technology. Thus, in this study we constructed specific HIF-1α siRNA interference sequences, and transfected these into hypoxic CBRH-7919 rat hepatoma cells to study the effects of HIF-1α silencing on the activation of the phosphatidylinositol 3’-kinase(PI3K)/AKT signaling pathway and the proliferation of hepatoma cells. Consequently, we found that the HIF-1α silencing significantly inhibits the activation of the PI3K/AKT signaling pathway and the proliferation of hypoxic CBRH-7919 rat hepatoma cells.

MATERIALS AND METHODS
Cell lines and cell culture

The CBRH-7919 rat hepatoma cell line was provided by the Central Laboratory of Sun Yat-Sen University (Guangzhou, China). The hepatoma cells were routinely grown in RPMI1640 medium, supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 100 U/mL streptomycin in a 37 °C incubator with 5% CO2. The cells were passaged every 2-3 d to maintain exponential growth.

Hypoxia model construction

Cells were plated in 60-mm dishes or 6-well plates according to the experimental requirements and were cultured at 37 °C with 5% CO2. In preparation for the experiment, the medium was replaced with a thin layer of fresh medium which contained 10% FCS to decrease the diffusion distance of the ambient gas. Different densities of CoCl2 (100, 150, 200 and 300 μmol/L) were then mixed into the culture dishes, and the samples were processed for 12 and 24 h. A control sample containing 0 μmol/L CoCl2 was also processed.

Design of siRNA and transfection studies

siRNAs targeted against HIF-1α were designed according to the gene coding sequence of rat HIF-1α obtained from GeneBank. The secondary structure of the HIF-1α gene sequence was analyzed using RNA draw software. Three potential target mRNA sequences were selected and siRNA sequences were determined using online design software (http://www.ambion.com/techlib/misc/sirna_finder.htm): 1:P1:5’-AGUGACUGAUUCUGGCAGCTT-3’, P2: 5’-GCUGCCAGAAUCAGUCACUTT-3’; 2:P1: 5’-GGAUGACUUUAAGCAAGAATT-3’, P2: 5’-UUCUUGCUUAAAGUCAUCCTT-3’; 3:P1: 5’-GAAACUCUUCCAAGCAAUUTT-3’, P2: 5’-AAUUGCUUGGAAGAGUUUCTT-3’. Based on the process of siRNA target sequence design, the silencer siRNAs were produced according to the sequence of the selected target mRNA. Then the siRNAs transfection mixture was produced by mixing the siRNA and Lipofectamine2000TM (Invitrogen, Carlsbad, CA, United States). The mixture containing siRNA sequences was then transfected into cultured cells, according to the manufacturer’s protocol. The cells were harvested 24 h after transfection for analyses. A subset of CBRH-7919 cells was treated only with Lipofectamine 2000 TM reagent as a control group.

Real time reverse transcription-polymerase chain reaction

RNA was extracted directly from all samples using TRIzol reagent (Invitrogen) followed by isopropanol precipitation. An RNA polymerase chain reaction (PCR) kit (TaKaRa) was used to obtain template cDNA for real-time PCR (ABI Prism 7500, Perkin Elmer, Foster City, CA, United States) using SYBR Premix Ex Taq (TaKaRa). Specific primer sequences were designed by TaKaRa as follows: HIF-1α: 5’-ACTGCACAGGCCACATTCAT-3’ (sense) and 5’-CGAGGCTGTGTCGACTGAGA-3’ (antisense); vascular endothelial growth factor (VEGF): 5’-AGGCGAGGCAGCTTGAGTTA-3’ (sense) and 5’-CTGTCGACGGTGACGATGGT-3’ (antisense); β-actin: 5’-CCTAGGCACCAGGGTGTGAT-3’ (sense) and 5’-TTGGTGACAATGCCGTGTTC-3’ (antisense). The initial denaturation phase was 3 min at 95 °C followed by 39 cycles of denaturation at 95 °C for 10 s and annealing at 55 °C for 30 s. Relative quantification of PCR products was performed after normalization to β-actin.

Western blotting

Cellular proteins were extracted with RIPA lysis buffer, and protein concentrations were measured by the Bradford method. Protein samples (20 μg/well) were separated by 10% sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, and electrophoretically transferred to nitrocellulose membranes. The membranes were then blocked for 60 min and subsequently incubated with primary antibodies (1:3000) overnight at 4 °C prior to incubation with anti-mouse IgG conjugated to horseradish peroxidase (1:6000) for 120 min at room temperature. Finally, after developing with enhanced chemiluminescence detection reagents, the protein bands of membranes were visualized by exposure to x-ray film. Protein expression was quantified by densitometry and normalized to β-actin expression. Anti-HIF-1α, anti-Akt/phosphorylated Akt, anti-VEGF, anti-p21, cyclinD1, and anti-β-actin, antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, United States).

Methyl thiazolyl tetrazolium cell proliferation assay

Cells were seeded into 96-well plates (Costar; Corning Inc., Corning, NY, United States) for 9 h. Following exposure to 0.5% O2, the cells were exposed to various concentrations of cisplatin or doxorubicin for 48 h in a CO2 incubator. Methyl thiazolyl tetrazolium (MTT) (10 μL; 5 g/L in PBS) was added to each well followed by incubation for 4 h at 37 °C. Subsequently, the formazan crystals were solubilized with 150 μL of 10% SDS in 0.01 mol/L HCl for 24 h. The absorbances at 500 nm relative to a reference wave length of 490 nm were determined with a microplate reader (Bio-Rad 680, Bio-Rad, United States). The absorbance values were expressed as percentages relative to the untreated controls, and the concentrations resulting in 50% inhibition of cell growth (IC50 values) were calculated.

Bromodeoxyuridine incorporation assay

CBRH-7919 cells were seeded in 96-well plates and treated with various drugs as indicated in each experiment for 48 h. At the end of treatment, bromodeoxyuridine (BrdU) incorporation was assayed by incubating the cells with BrdU for 0.5-1 h using a BrdU Cell Proliferation Assay Kit (Calbiochem, San Diego, CA, United States) according to the manufacturer’s instructions.

Statistical analysis

All experimental data were expressed as mean ± SD. Comparisons between two groups were made using the Student’s t-test. Statistical significance was determined by analysis of variance followed by Fisher’s least significant difference analysis using the SPSS 19.0 software package. The statistical significance level was set at P < 0.05.

RESULTS
Viability of hepatoma cells under hypoxia

CBRH-7919 hepatoma cells were cultured in a hypoxia model, which was constructed using various concentrations of CoCl2 (Figure 1). The viability of hepatoma cells under hypoxia was observed using MTT, and the results of the analysis indicated that the viability of hepatoma cells was gradually decreased as CoCl2 concentrations increased from 100 μmol/L to 800 μmol/L. The viability of the hepatoma cells reached a minimum at 800 μmol/L CoCl2; however, the viability of the cells was relatively high at CoCl2 concentrations between 100 μmol/L and 200 μmol/L (Figure 1).

Figure 1
Open in New Tab   Full Size Figure   Download Figure
Figure 1 Viability of hepatoma cells under hypoxia was measured using methyl thiazolyl tetrazolium cell proliferation assay. A: Histograms; B: Polygon.
Hypoxia increased the expressions of HIF-1α and VEGF

Hepatoma cells were cultured under 0, 100, 150, 200 and 300 μmol/L CoCl2 using processing times of 12 and 24 h, respectively. CoCl2 at 0 μmol/L was the control group. The results of real-time RT-PCR assay indicated that the mRNA levels of HIF-1α and VEGF gradually increased as the concentrations of CoCl2 increased from 0 μmol/L to 200 μmol/L with a 12 h processing time and the expression levels of HIF-1α and VEGF reached a maximum at 200 μmol/L CoCl2 (Figure 2). However, the expressions of HIF-1α and VEGF were declined as the concentration of CoCl2 reached 300 μmol/L. When the processing time was increased to 24 h, the expression levels of HIF-1α and VEGF were higher than those observed at 12 h. Additionally, the protein expression levels of HIF-1α and VEGF demonstrated the same patterns as their respective mRNA expression levels (Figure 3).

Figure 2
Open in New Tab   Full Size Figure   Download Figure
Figure 2 mRNA expression levels of hypoxia-inducible factor-1α and vascular endothelial growth factor. A, B: Histograms illustrating hypoxia-inducible factor-1α (HIF-1α) mRNA expression after exposure to various concentrations of CoCl2 for 12 h and 24 h; C, D: Histograms illustrating vascular endothelial growth factor (VEGF) mRNA expression after exposure to various concentrations of CoCl2 for 12 h and 24 h.
Figure 3
Open in New Tab   Full Size Figure   Download Figure
Figure 3 Protein expression levels of hypoxia-inducible factor-1α and vascular endothelial growth factor after exposure to 0-300 μmol/L CoCl2 for 12 and 24 h. A, B: The Western blotting analysis of protein expression levels of hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF); C, D: Histograms illustrating HIF-1α protein expression after exposure to various concentrations of CoCl2 for 12 h and 24 h; E, F: Histograms illustrating VEGF protein expression after exposure to various concentrations of CoCl2 for 12 h and 24 h.
Expressions of HIF-1α and VEGF were inhibited by siRNA interference

Based on the previous phase of our study, the optimal hypoxia-mimicking condition was determined to be the concentration of 150 μmol/L CoCl2 with a 24 h processing time. Thus, CBRH-7919 hepatoma cells were cultured under these conditions prior to the next step of the experiment. The specific siRNA sequences were designed and the hepatoma cells were transfected using three different groups of specific siRNA vectors. The protein and mRNA expression levels of HIF-1α and VEGF were measured using real-time RT-PCR and western blot analysis, respectively. The results indicated that both the mRNA and protein expression levels of HIF-1α and VEGF were significantly decreased after the transfection with specific siRNA sequences with a processing time of 24 h (Figures 4 and 5). However, there were no differences in the mRNA and protein expression levels of HIF-1α and VEGF of hepatoma cells in the control group.

Figure 4
Open in New Tab   Full Size Figure   Download Figure
Figure 4 Histograms illustrating hypoxia-inducible factor-1α (A) and vascular endothelial growth factor (B) mRNA expression after small interfering RNAs transfection (24 h processing time). siRNA: Small interfering RNA.
Figure 5
Open in New Tab   Full Size Figure   Download Figure
Figure 5 Protein expression levels of hypoxia-inducible factor-1α and vascular endothelial growth factor after small interfering RNAs transfection (24 h processing time). A: The Western blotting analysis of protein expression levels of hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) after small interfering RNA (siRNA) transfection; B, C: Histograms illustrating HIF-1α (B) and VEGF (C) protein expression after siRNA transfection. NC: Control group without siRNA transfection; Ri1, Ri2, Ri3: Three different specific siRNA sequences.
Effects of HIF-1α silencing on the expressions of VEGF, AKT, p-AKT, p21 and cyclinD1

Based on the previous phases of our study, the specific siRNA sequence “Ri3” was selected for the next phase of this study. “Ri3” was transfected into the hepatoma cells cultured with 150 μmol/L CoCl2 with a 24 h processing time, and Western blotting analysis was performed to detect the protein expression levels of HIF-1α, VEGF, AKT, p-AKT, p21 and cyclinD1. The results indicated that the protein expression levels of HIF-1α, VEGF, p-AKT and cyclinD1 were significantly decreased compared with those of the control group; however, the expression of p21 protein was significantly increased and there was no significance difference in the expression of AKT protein (Figure 6).

Figure 6
Open in New Tab   Full Size Figure   Download Figure
Figure 6 Protein expression levels of p-AKT, AKT, p21, cyclinD1, vascular endothelial growth factor and hypoxia-inducible factor-1α after the transfection with specific small interfering RNAs (processing time of 24 h). A: The Western blotting analysis of protein expression levels of p-AKT, AKT, p21, cyclinD1, vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1α (HIF-1α) after specific small interfering RNA (siRNA) transfection; B-G: Histograms illustrating p-AKT (B), AKT (C), p21 (D), cyclinD1(E), VEGF (F) and HIF-1α (G) protein expression after specific siRNA transfection.
Effects of HIF-1α silencing on the proliferation of hepatoma cells

In consideration of the functions of p21 and cyclinD1 in the cell cycle, the decrease in the expressions of p21 and cyclinD1 caused by HIF-1α silencing suggested that the knockdown of HIF-1α may suppress the proliferation of the hepatoma cells. Thus, we studied the effects of HIF-1α-specific siRNAs on the proliferation of the CBRH-7919 hepatoma cells. HIF-1α-specific siRNAs or controls were transfected using Lipofectamine 2000TM and the proliferation of hepatoma cells was determined using the MTT assay and the BrdU incorporation assay at 24 h after the transfection. The results of the MTT assay and BrdU incorporation assay indicated that the HIF-1α silencing significantly inhibited the proliferation of CBRH-7919 hepatoma cells when compared with the control group at the processing time of 24 h (Figures 7 and 8 ).

Figure 7
Open in New Tab   Full Size Figure   Download Figure
Figure 7 Methyl thiazolyl tetrazolium cell proliferation assay indicated that the hypoxia-inducible factor-1α silencing via specific small interfering RNAs significantly inhibited the proliferation of CBRH-7919 hepatoma cells. A: Contro group; B: Processing time of 24 h.
Figure 8
Open in New Tab   Full Size Figure   Download Figure
Figure 8 Proliferation of hepatoma cells detected by bromodeoxyuridine incorporation illustrates that hypoxia-inducible factor-1α silencing via specific small interfering RNAs significantly inhibited the proliferation of CBRH-7919 hepatoma cells. DAPI: 4',6'-diamidino-2-phenylindole hydrochloride; BrdU: Bromodeoxyuridine.
DISCUSSION

The hypoxia inducible transcription factors mediate the primary transcriptional responses to hypoxic stress in normal and transformed cells[15]. HIF-1α was firstly described by Semenza in 1992 and was shown to play a critical role in mediating O2-dependent transcriptional responses. HIF-1 activity in tumors depends on the availability of the HIF-1α subunit, the expression level of which is increased under hypoxic conditions and is associated with the activation of oncogenes and/or the inactivation of tumor suppressor genes. Over-expression of HIF-1α has been correlated with increased angiogenesis, tumor progression, invasion, metastasis and poor patient prognosis, and this has led to the current interest in HIF-1α as a promising anticancer genetic target for anticancer therapies[16,17].

In this study, rat CBRH-7919 hepatoma cells were cultured in a hypoxic model constructed using CoCl2, and specific HIF-1α siRNA sequences were designed and transfected into hypoxic hepatoma cells. Our study demonstrated that the expressions of HIF-1α, VEGF, p-AKT and cyclinD1 were significantly decreased compared with those of the control group; however, the expression of p21 was significantly increased and there was no significant difference in the expression of AKT. This finding indicates that silencing of HIF-1α using specific siRNA can inhibit the expressions of VEGF, p-AKT and cyclinD1 while up-regulating the expression of p21. The subsequent MTT cell proliferation and BrdU incorporation assays revealed that the proliferation of hepatoma cells was significantly inhibited by HIF-1α silencing.

The PI3K/AKT signaling transduction pathway is one of the most important pathways inside human cancer and plays a critical role in various cellular functions, such as proliferation, adhesion, migration, invasion, metabolism and survival[18-20]. The activation of the PI3K/AKT signaling pathway depends on the expression of p-AKT (phosphorylated AKT). Over-expression of p-AKT is one of the most common indications of human malignancies, such as gastric cancer, liver cancer, colorectal cancer, pancreatic cancer and breast cancer[21,22]. Additionally, p-AKT is believed to play an important role in cancer cell survival and chemotherapy resistance. In our study, although there was no significant difference in the expression of AKT, the expression of p-AKT was significantly inhibited after the specific siRNA sequences were transfected into hepatoma cells. This indicated that the silencing of HIF-1α using specific siRNAs inhibited the activation of the PI3K/AKT signaling transduction pathway. The inhibition of the PI3K/AKT signaling pathway may be associated with inhibition of the activation of the PI3K-independent pathway. Under hypoxia or within tumor cells, the normal degradation of HIF-1α is inhibited and HIF-1α accumulates in the nucleus, which promotes the activation of downstream targeted genes and activates AKT[23-25]. Over-expression of VEGF is also observed in various types of human cancer cells. VEGF promotes the proliferation of vessel endothelial cells, inhibits the apoptosis of vessel endothelial cells, and stimulates the formation of blood vessels. Previous studies reported that VEGF alone can activate the PI3K/AKT pathway[26,27]. Hence, it is indicated that inhibition of the expression of VEGF by HIF-1α silencing may affect the activation of the PI3K/AKT pathway. p21 and cyclinD1 are the downstream targets of the PI3K/AKT signaling transduction pathway and their expressions are also regulated by the pathway[28,29]. Our data revealed that the expression of p21 was significantly increased; however, the expression of cyclinD1 was significantly decreased after HIF-1α was silenced by specific siRNAs. The results of our study provide strong evidence to support our hypothesis that the activation of the PI3K/AKT signaling pathway can be inhibited by HIF-1α silencing.

Considering the functions of p21 and cyclinD1 in cell cycle processing[30-34], HIF-1α silencing may have an effect on PI3K/AKT signaling pathway-dependent proliferation of hepatoma cells as well. In our study, the results of the MTT cell proliferation and BrdU incorporation assays indicated that the transfection of specific siRNAs effectively increased the number of cells in G0/G1 phase, and the numbers of cells in S and G2/M phases were significantly decreased compared with those of the control group. Additionally, the proportion of BrdU-positive cells in the siRNA interference group was smaller than that of the control group. Taken together, these data indicate that HIF-1α silencing by the specific siRNAs can significantly inhibit the activation of the PI3K/AKT signaling transduction pathway and the proliferation of hepatoma cells.

HIF-1α is currently accepted as one of the most important genetic targets for anticancer therapy. However, to our knowledge, there have only been a few studies examining the effects of HIF-1α on the proliferation of hepatoma cells. Our study demonstrated that HIF-1α silencing can inhibit the proliferation of hypoxic rat CBRH-7919 hepatoma cells. However, the correlation between HIF-1α and the PI3K/AKT signaling transduction pathway is still contested[35-38] and further research is urgently needed to provide new evidence. The evidence obtained in our study indicated that HIF-1α can be silenced using specific siRNAs and that the silencing of HIF-1α can significantly inhibit the activation of the PI3K/AKT signal transduction pathway.

Transcatheter arterial chemoembolization (TACE) is the most commonly used palliative treatment for HCC in clinical practice[39-41]. However, the hypoxic microenvironment of tumor tissue after TACE often induces high expression levels of HIF-1α and promotes tumor progression, invasion and metastasis of tumor, providing a poor prognosis for patients with HCC. Thus, the long-term results of TACE are not satisfying. The combination of TACE and siRNA interference for the treatment of HCC can be expected to down-regulate the expression of HIF-1α after TACE. Unfortunately, it is unclear whether the effects of siRNA interference in vivo are the same as (or similar to) that which are observed in vitro. Thus, further studies are required to explore the effects of siRNA interference in vivo.

COMMENTS
Background

The over-expression of hypoxia-inducible factor-1α (HIF-1α) has been demonstrated in multiple types of malignant tumors. HIF-1α contributes to tumor angiogenesis and metastasis and plays a critical role in mediating O2-dependent transcriptional responses. Preliminary tests showed that it is possible to silence HIF-1α using small interfering RNA (siRNA) interference technology.

Research frontiers

Gene therapy is a potential treatment for malignant tumors and some other diseases. siRNAs have been widely demonstrated as effective biomedical genetic-therapy applications for many diseases. In this study, the authors demonstrate that HIF-1α silencing using siRNAs can significantly inhibit the proliferation of hepatoma cells, which could be a potential gene therapy for anti-cancer treatment.

Innovations and breakthroughs

Previous studies reported that HIF-1α contributes to tumor angiogenesis and metastasis and plays a critical role in mediating O2-dependent transcriptional responses. However, the relationship between HIF-1α and the PI3K/AKT signaling pathway, and the effects of HIF-1α on the proliferation of hepatoma cells, have not been unequivocally addressed. The results of this study showed that HIF-1α silencing can significantly inhibit the activation of the PI3K/AKT signaling pathway and the proliferation of hepatoma cells. This study proves that HIF-1α could be an effective and important gene target for anti-cancer treatment.

Applications

By understanding the effect of HIF-1α silencing on the PI3K/AKT signaling pathway and the proliferation of hepatoma cells, an effective gene target has been identified for the gene treatment of hepatocellular carcinoma (HCC), providing an experimental basis for the clinical practice of gene therapies for malignant tumors.

Terminology

HIF-1α has been correlated with increased angiogenesis, tumor progression, invasion, metastasis and poor patient prognosis. In this study, HIF-1α was silenced using siRNA technology. It demonstrated that HIF-1α silencing significantly inhibited the activation of the PI3K/AKT signaling pathway and the proliferation of hepatoma cells, and HIF-1α was proved to be an effective gene target for the gene therapy of HCC.

Peer review

This paper reported that hypoxia induces HIF-1α expression, and knocking-down HIF-1α by siRNA inhibits the PI3K/AKT signaling pathway and the proliferation of hypoxic CBRH-7919 rat hepatoma cells. Those findings indicate HIF-1α could be a potential drug target for cancer therapy.

Footnotes

P- Reviewer Wang M S- Editor Song XX L- Editor Logan S E- Editor Zhang DN

References
1.  Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, Heathcote J, Piratsivuth T, Kew M, Otegbayo JA. Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol. 2010;44:239-245.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 200]  [Cited by in F6Publishing: 205]  [Article Influence: 13.7]  [Reference Citation Analysis (0)]
2.  Kouri BE, Funaki BS, Ray CE, Abou-Alfa GK, Burke CT, Darcy MD, Fidelman N, Greene FL, Harrison SA, Kinney TB. ACR Appropriateness Criteria radiologic management of hepatic malignancy. J Am Coll Radiol. 2012;9:919-925.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2]  [Cited by in F6Publishing: 4]  [Article Influence: 0.3]  [Reference Citation Analysis (0)]
3.  Mohr SE, Perrimon N. RNAi screening: new approaches, understandings, and organisms. Wiley Interdiscip Rev RNA. 2012;3:145-158.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 96]  [Cited by in F6Publishing: 97]  [Article Influence: 6.9]  [Reference Citation Analysis (0)]
4.  Lares MR, Rossi JJ, Ouellet DL. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol. 2010;28:570-579.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 208]  [Cited by in F6Publishing: 211]  [Article Influence: 14.1]  [Reference Citation Analysis (0)]
5.  Rocheleau CE. RNA interference: Systemic RNAi SIDes with endosomes. Curr Biol. 2012;22:R873-R875.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 14]  [Cited by in F6Publishing: 14]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]
6.  Mackenzie KA, Miller AP, Hock BD, Gardner J, Simcock JW, Roake JA, Dachs GU, Robinson BA, Currie MJ. Angiogenesis and host immune response contribute to the aggressive character of non-melanoma skin cancers in renal transplant recipients. Histopathology. 2011;58:875-885.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 13]  [Article Influence: 0.9]  [Reference Citation Analysis (0)]
7.  Chen Y, Zhang L, Pan Y, Ren X, Hao Q. Over-Expression of Semaphorin4D, Hypoxia-Inducible Factor-1& amp; alpha; and Vascular Endothelial Growth Factor Is Related to Poor Prognosis in Ovarian Epithelial Cancer. Int J Mol Sci. 2012;13:13264-13274.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 32]  [Cited by in F6Publishing: 36]  [Article Influence: 2.8]  [Reference Citation Analysis (0)]
8.  Finlay DK, Rosenzweig E, Sinclair LV, Feijoo-Carnero C, Hukelmann JL, Rolf J, Panteleyev AA, Okkenhaug K, Cantrell DA. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J Exp Med. 2012;209:2441-2453.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 400]  [Cited by in F6Publishing: 462]  [Article Influence: 35.5]  [Reference Citation Analysis (0)]
9.  Jin X, Jin HR, Lee D, Lee JH, Kim SK, Lee JJ. A quassinoid 6alpha-tigloyloxychaparrinone inhibits hypoxia-inducible factor-1 pathway by inhibition of eukaryotic translation initiation factor 4E phosphorylation. Eur J Pharmacol. 2008;592:41-47.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 18]  [Cited by in F6Publishing: 14]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
10.  Lee K, Kim HM. A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor. Arch Pharm Res. 2011;34:1583-1585.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 43]  [Cited by in F6Publishing: 65]  [Article Influence: 5.4]  [Reference Citation Analysis (0)]
11.  Leontieva OV, Natarajan V, Demidenko ZN, Burdelya LG, Gudkov AV, Blagosklonny MV. Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proc Natl Acad Sci USA. 2012;109:13314-13318.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 125]  [Cited by in F6Publishing: 137]  [Article Influence: 10.5]  [Reference Citation Analysis (0)]
12.  Zhou H, Fei W, Bai Y, Zhu S, Luo E, Chen K, Hu J. RNA interference-mediated downregulation of hypoxia-inducible factor-1α inhibits angiogenesis and survival of oral squamous cell carcinoma in vitro and in vivo. Eur J Cancer Prev. 2012;21:289-299.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8]  [Cited by in F6Publishing: 10]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
13.  Min L, Chen Q, He S, Liu S, Ma Y. Hypoxia-induced increases in A549/CDDP cell drug resistance are reversed by RNA interference of HIF-1α expression. Mol Med Rep. 2012;5:228-232.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3]  [Cited by in F6Publishing: 10]  [Article Influence: 0.7]  [Reference Citation Analysis (0)]
14.  Bove PF, Hristova M, Wesley UV, Olson N, Lounsbury KM, van der Vliet A. Inflammatory levels of nitric oxide inhibit airway epithelial cell migration by inhibition of the kinase ERK1/2 and activation of hypoxia-inducible factor-1 alpha. J Biol Chem. 2008;283:17919-17928.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 31]  [Cited by in F6Publishing: 35]  [Article Influence: 2.1]  [Reference Citation Analysis (0)]
15.  Keith B, Johnson RS, Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2012;12:9-22.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1159]  [Cited by in F6Publishing: 1346]  [Article Influence: 96.1]  [Reference Citation Analysis (0)]
16.  Capparelli C, Whitaker-Menezes D, Guido C, Balliet R, Pestell TG, Howell A, Sneddon S, Pestell RG, Martinez-Outschoorn U, Lisanti MP. CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. Cell Cycle. 2012;11:2272-2284.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 99]  [Cited by in F6Publishing: 107]  [Article Influence: 8.2]  [Reference Citation Analysis (0)]
17.  Miyake K, Nishioka M, Imura S, Batmunkh E, Uto Y, Nagasawa H, Hori H, Shimada M. The novel hypoxic cytotoxin, TX-2098 has antitumor effect in pancreatic cancer; possible mechanism through inhibiting VEGF and hypoxia inducible factor-1α targeted gene expression. Exp Cell Res. 2012;318:1554-1563.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 18]  [Cited by in F6Publishing: 23]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]
18.  Shah A, Silverstein PS, Kumar S, Singh DP, Kumar A. Synergistic cooperation between methamphetamine and HIV-1 gsp120 through the P13K/Akt pathway induces IL-6 but not IL-8 expression in astrocytes. PLoS One. 2012;7:e52060.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 24]  [Cited by in F6Publishing: 26]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
19.  Britschgi A, Andraos R, Brinkhaus H, Klebba I, Romanet V, Müller U, Murakami M, Radimerski T, Bentires-Alj M. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell. 2012;22:796-811.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 181]  [Cited by in F6Publishing: 191]  [Article Influence: 14.7]  [Reference Citation Analysis (0)]
20.  Pópulo H, Lopes JM, Soares P. The mTOR Signalling Pathway in Human Cancer. Int J Mol Sci. 2012;13:1886-1918.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 609]  [Cited by in F6Publishing: 587]  [Article Influence: 45.2]  [Reference Citation Analysis (0)]
21.  Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep. 2012;14:129-138.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 132]  [Cited by in F6Publishing: 149]  [Article Influence: 11.5]  [Reference Citation Analysis (0)]
22.  Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:121-130.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 144]  [Cited by in F6Publishing: 157]  [Article Influence: 12.1]  [Reference Citation Analysis (0)]
23.  Chang LH, Chen CH, Huang DY, Pai HC, Pan SL, Teng CM. Thrombin induces expression of twist and cell motility via the hypoxia-inducible factor-1α translational pathway in colorectal cancer cells. J Cell Physiol. 2011;226:1060-1068.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 29]  [Cited by in F6Publishing: 32]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
24.  Fu J, Chen Y, Cao J, Luo T, Qian YW, Yang W, Ren YB, Su B, Cao GW, Yang Y. p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1α pathways. Hepatology. 2011;53:181-192.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 104]  [Cited by in F6Publishing: 107]  [Article Influence: 7.6]  [Reference Citation Analysis (0)]
25.  Polosukhin VV, Cates JM, Lawson WE, Milstone AP, Matafonov AG, Massion PP, Lee JW, Randell SH, Blackwell TS. Hypoxia-inducible factor-1 signalling promotes goblet cell hyperplasia in airway epithelium. J Pathol. 2011;224:203-211.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 40]  [Cited by in F6Publishing: 45]  [Article Influence: 3.2]  [Reference Citation Analysis (0)]
26.  Eichmann A, Simons M. VEGF signaling inside vascular endothelial cells and beyond. Curr Opin Cell Biol. 2012;24:188-193.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 174]  [Cited by in F6Publishing: 195]  [Article Influence: 15.0]  [Reference Citation Analysis (0)]
27.  Chiusa M, Hool SL, Truetsch P, Djafarzadeh S, Jakob SM, Seifriz F, Scherer SJ, Suter TM, Zuppinger C, Zbinden S. Cancer therapy modulates VEGF signaling and viability in adult rat cardiac microvascular endothelial cells and cardiomyocytes. J Mol Cell Cardiol. 2012;52:1164-1175.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 18]  [Cited by in F6Publishing: 26]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
28.  Harashima N, Inao T, Imamura R, Okano S, Suda T, Harada M. Roles of the PI3K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells. Cancer Immunol Immunother. 2012;61:667-676.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 67]  [Cited by in F6Publishing: 42]  [Article Influence: 3.2]  [Reference Citation Analysis (0)]
29.  Kang S, Dong SM, Kim BR, Park MS, Trink B, Byun HJ, Rho SB. Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells. Apoptosis. 2012;17:989-997.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 92]  [Cited by in F6Publishing: 105]  [Article Influence: 8.8]  [Reference Citation Analysis (0)]
30.  Zhou Y, Su J, Shi L, Liao Q, Su Q. DADS downregulates the Rac1-ROCK1/PAK1-LIMK1-ADF/cofilin signaling pathway, inhibiting cell migration and invasion. Oncol Rep. 2013;29:605-612.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 42]  [Cited by in F6Publishing: 46]  [Article Influence: 3.5]  [Reference Citation Analysis (0)]
31.  Jung YS, Qian Y, Chen X. Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal. 2010;22:1003-1012.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 326]  [Cited by in F6Publishing: 328]  [Article Influence: 21.9]  [Reference Citation Analysis (0)]
32.  Strzalka W, Ziemienowicz A. Proliferating cell nuclear antigen (PCNA): a key factor in DNA replication and cell cycle regulation. Ann Bot. 2011;107:1127-1140.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 416]  [Cited by in F6Publishing: 494]  [Article Influence: 35.3]  [Reference Citation Analysis (0)]
33.  Feng Z, Chen J, Wei H, Gao P, Shi J, Zhang J, Zhao F. The risk factor of gallbladder cancer: hyperplasia of mucous epithelium caused by gallstones associates with p16/CyclinD1/CDK4 pathway. Exp Mol Pathol. 2011;91:569-577.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 19]  [Cited by in F6Publishing: 19]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
34.  Fu X, Tan D, Hou Z, Hu Z, Liu G. miR-338-3p Is Down-Regulated by Hepatitis B Virus X and Inhibits Cell Proliferation by Targeting the 3’-UTR Region of CyclinD1. Int J Mol Sci. 2012;13:8514-8539.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 33]  [Cited by in F6Publishing: 38]  [Article Influence: 2.9]  [Reference Citation Analysis (0)]
35.  Ulici V, Hoenselaar KD, Agoston H, McErlain DD, Umoh J, Chakrabarti S, Holdsworth DW, Beier F. The role of Akt1 in terminal stages of endochondral bone formation: angiogenesis and ossification. Bone. 2009;45:1133-1145.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 76]  [Cited by in F6Publishing: 70]  [Article Influence: 4.4]  [Reference Citation Analysis (0)]
36.  Li GQ, Zhang Y, Liu D, Qian YY, Zhang H, Guo SY, Sunagawa M, Hisamitsu T, Liu YQ. PI3 kinase/Akt/HIF-1α pathway is associated with hypoxia-induced epithelial-mesenchymal transition in fibroblast-like synoviocytes of rheumatoid arthritis. Mol Cell Biochem. 2013;372:221-231.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 70]  [Cited by in F6Publishing: 77]  [Article Influence: 6.4]  [Reference Citation Analysis (0)]
37.  Yang XM, Wang YS, Zhang J, Li Y, Xu JF, Zhu J, Zhao W, Chu DK, Wiedemann P. Role of PI3K/Akt and MEK/ERK in mediating hypoxia-induced expression of HIF-1alpha and VEGF in laser-induced rat choroidal neovascularization. Invest Ophthalmol Vis Sci. 2009;50:1873-1879.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 108]  [Cited by in F6Publishing: 119]  [Article Influence: 7.0]  [Reference Citation Analysis (0)]
38.  Hong SW, Jung KH, Lee HS, Choi MJ, Son MK, Zheng HM, Hong SS. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway. Cancer Sci. 2012;103:1929-1937.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 35]  [Cited by in F6Publishing: 40]  [Article Influence: 3.1]  [Reference Citation Analysis (0)]
39.  Nakanishi C, Sato K, Ito Y, Abe T, Akada T, Muto R, Sakashita K, Konno T, Kato H, Satomi S. Combined hepatocellular carcinoma and neuroendocrine carcinoma with sarcomatous change of the liver after transarterial chemoembolization. Hepatol Res. 2012;42:1141-1145.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 20]  [Cited by in F6Publishing: 26]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
40.  Shinagawa Y, Sakamoto K, Fujimitsu R, Shimakura M, Kora S, Takano K, Yoshimitsu K. Pseudolesion of the liver on gadoxetate disodium-enhanced MR images obtained after transarterial chemoembolization for hepatocellular carcinoma: clinicoradiologic correlation. AJR Am J Roentgenol. 2012;199:1010-1017.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 14]  [Cited by in F6Publishing: 15]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
41.  Chan SL, Mok T, Ma BB. Management of hepatocellular carcinoma: beyond sorafenib. Curr Oncol Rep. 2012;14:257-266.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 23]  [Cited by in F6Publishing: 23]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]